Benefits and risks of anthracyclines in early-stage breast cancer - Authors' reply

Lancet. 2024 Mar 30;403(10433):1240. doi: 10.1016/S0140-6736(23)02890-8.

Authors

Jeremy Braybrooke¹, Rosie Bradley², Richard Gray¹, Robert Hills¹; Early Breast Cancer Trialists' Collaborative Group

Affiliations

¹ Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
² Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK. Electronic address: rosie.bradley@ndph.ox.ac.uk.

PMID: 38555133
DOI: 10.1016/S0140-6736(23)02890-8

No abstract available

Publication types

Letter

MeSH terms

Anthracyclines / adverse effects
Antibiotics, Antineoplastic
Breast Neoplasms* / drug therapy
Female
Humans
Risk Assessment
Taxoids / therapeutic use

Substances

Anthracyclines
Antibiotics, Antineoplastic
Taxoids